Hospitals, doctors are ignoring RFK Jr.’s new vaccine schedule

The rejection of the federal schedule could be a blow to Kennedy's aim of restoring trust.

January 15, 2026 Check out STAT+

Sponsored By

Want unlimited access to STAT? Become a subscriber for less than $4 a week. Thanks for reading!

Paul Vernon/AP Hospitals and doctors are ignoring RFK Jr.'s new vaccine schedule and relying on pediatricians' guidance instead Leading health systems plan to follow the vaccine schedule from the American Academy of Pediatrics, which largely matches the previous U.S. policy. By Daniel Payne STAT+ | Trump releases health care plan amid pressure over affordability Trump's plan addresses multiple thorny issues, including moving some prescription drugs to OTC status and changing how PBMs operate. By Daniel Payne, Bob Herman, and John Wilkerson STAT+ | Regeneron's chief scientist on Trump's drug pricing policy, gene therapy, and the problem with AI At the JP Morgan Healthcare Conference, the longtime biotech executive was, as usual, outspoken in an interview with STAT. By Matthew Herper AP Opinion: My grandfather created the hepatitis B vaccine. Would he recognize public health in the U.S. today? Vaccines save more than the life of the vaccinated. It's an individual act against the spread of disease. A First Opinion essay by Emilie G.C. Thompson. By Emilie G.C. Thompson Democrats say America's role as a scientific leader is slipping, while Republicans remain unworried A new survey by the Pew Research Center also highlights a partisan split on many key issues, including the country's scientific standing globally. By Anil Oza Enrollment in biomedical degree programs rose last fall despite funding turmoil, new data show U.S. biomedical enrollment rose in 2025, even as Trump administration research cuts slowed graduate growth and raised long-term concerns By Jonathan Wosen Adobe STAT+ | Opinion: After FDA's pivot on clinical AI, we need AI safety research more than ever Recent developments from the FDA, OpenAI, and Doctronic have rapidly made theoretical safety concerns real. By Katherine E. Goodman and Daniel Morgan STAT+ | Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y. The New York attorney general says Kramer sold millions in stock after becoming aware of contamination issues in connection with a Covid-era contract. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser